A Study of Semorinemab in Patients With Moderate Alzheimer's Disease
Status:
Active, not recruiting
Trial end date:
2023-10-20
Target enrollment:
Participant gender:
Summary
This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group
study will evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of
semorinemab in patients with moderate AD. The study consists of a screening period, a
double-blind treatment period, an optional open-label extension (OLE) period, and a safety
follow-up period. There may be up to three study cohorts.